Table 6.
Characteristics of Cohort 2 (METABRIC) (Normal-like and basal-like subtypes excluded from the analyses)
| Total study population | Discovery cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
| Total | Mean probe MRPS23 | χ2 | ||||
| Quartile 1–3a | Quartile 4b | |||||
| N (%) | 1434 | 1069 | 365 | 804 (56) | 630 (44) | |
| Mean age at diagnosis, years (SD) | 63.2 (12.4) | 63.6 (12.4) | 62 (12.4) | 62.3 (12.5) | 64.3 (12.2) | |
| Mean follow-up, years (SD) | 8.3 (4.9) | 8.5 (5) | 7.8 (4.5) | 8.1 (4.7) | 8.5 (5.1) | |
| Deaths from BC (%) | 354 (25) | 273 (25) | 81 (22) | 201 (25) | 153 (24) | |
| Deaths from other causes (%) | 311 (22) | 240 (22) | 71 (19) | 156 (19) | 155 (25) | |
| Histologic grade (%) | ||||||
| I | 139 (10) | 116 (11) | 23 (6) | < 0.001 | 61 (8) | 78 (12) |
| II | 635 (44) | 504 (47) | 131 (36) | 375 (47) | 260 (41) | |
| III | 598 (42) | 392 (17) | 206 (56) | 368 (46) | 230 (37) | |
| Unknown | 62 (4) | 57 (5) | 5 (1) | 0 | 62 (10) | |
| Lymph node metastasis (%) | ||||||
| Yes | 684 (48) | 491 (46) | 193 (53) | 0.030 | 383 (48) | 301 (48) |
| No | 750 (52) | 578 (54) | 172 (47) | 421 (52) | 329 (52) | |
| Tumour size (%) | ||||||
| ≤ 2 cm | 613 (43) | 472 (44) | 141 (39) | 0.170 | 351 (42) | 262 (42) |
| > 2 cm, ≤ 5 cm | 751 (52) | 542 (51) | 209 (57) | 421 (52) | 330 (53) | |
| > 5 cm | 69 (5) | 54 (5) | 15 (4) | 32 (4) | 37 (6) | |
| Uncertain | 1 (0) | 1 (0) | 0 | 0 | 1 (0) | |
| Stage (%) | ||||||
| I | 104 (7) | 84 (8) | 20 (5) | 0.075 | 0 | 104 (17) |
| II | 177 (12) | 141 (13) | 36 (10) | 0 | 177 (28) | |
| III | 27 (2) | 20 (2) | 7 (2) | 0 | 27 (4) | |
| IV | 1 (0) | 0 | 1 (0) | 0 | 1 (0) | |
| Unknown | 1125 (78) | 824 (77) | 301 (82) | 804 (100) | 321 (50) | |
| PAM50 subtype (%) | ||||||
| Luminal A | 709 (49) | 606 (57) | 103 (28) | 445 (56) | 255 (40) | |
| Luminal B | 488 (34) | 276 (26) | 212 (58) | 266 (33) | 222 (35) | |
| HER2-type | 237 (17) | 187 (17) | 50 (14) | < 0.001 | 84 (10) | 153 (25) |
N number of patients, SD standard deviation, BC breast cancer
aMean probe MRPS23 ≤ 8.31
bMean probe MRPS23 > 8.31